Among PRRs, activation of retinoic acid‐inducible gene‐I (RIG‐I)‐like receptors (RLRs), which include melanoma differentiation‐associated gene 5 (MDA5) and RIG‐I in cancer cells, is suggested as beneficial strategy in the treatment of TNBC due to the fact that the RIG‐I gene is rarely mutated or deleted [8]. This evidence concerns the gene IFIH1 and cancer.